Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Equity Ratio (2019 - 2025)

Historic Equity Ratio for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to 0.72.

  • Allogene Therapeutics' Equity Ratio fell 891.24% to 0.72 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.72, marking a year-over-year decrease of 891.24%. This contributed to the annual value of 0.77 for FY2024, which is 344.23% down from last year.
  • Per Allogene Therapeutics' latest filing, its Equity Ratio stood at 0.72 for Q3 2025, which was down 891.24% from 0.73 recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Equity Ratio high stood at 0.91 for Q2 2021, and its period low was 0.72 during Q3 2025.
  • Moreover, its 5-year median value for Equity Ratio was 0.8 (2023), whereas its average is 0.82.
  • Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 300.02% in 2021, then plummeted by 1078.81% in 2023.
  • Quarter analysis of 5 years shows Allogene Therapeutics' Equity Ratio stood at 0.88 in 2021, then dropped by 7.81% to 0.81 in 2022, then decreased by 1.83% to 0.8 in 2023, then fell by 3.44% to 0.77 in 2024, then dropped by 6.81% to 0.72 in 2025.
  • Its Equity Ratio stands at 0.72 for Q3 2025, versus 0.73 for Q2 2025 and 0.76 for Q1 2025.